New AI platforms aim to streamline cancer trial recruitment and design
At SCOPE 2026 in Orlando, leading life-sciences vendors unveiled AI-based platforms designed to tackle key clinical trial challenges, especially patient recruitment and study design, to shorten timelines and improve outcomes in oncology research.
At the Summit for Clinical Operations Executives (SCOPE) 2026, major players in life sciences showcased artificial intelligence-enabled systems built to accelerate and optimise oncology clinical trials.
Massive Bio’s TrialRelay uses AI routing (“TrialRouter”) to orchestrate the enrolment process, reducing the risk that patients are lost in the referral pipeline after being matched to a study.
ConcertAI’s Accelerated Clinical Trials (ACT) platform, powered by its proprietary agentic AI, integrates real-world and proprietary datasets with advanced workflows to shorten trial timelines by 10–20 months, improve study design and reduce costly amendments, helping sponsors and contract research organisations (CROs) bring therapies to patients faster.
AI adoption in clinical research is rising across recruitment, trial design, data handling and operational forecasting, though integration challenges, regulatory alignment and rapid technological change remain obstacles.
Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!